Abstract 1591: Src is activated in cervical adenocarcinoma

Abstract Src family tyrosine kinases are important factors for cell growth. Src is reported to be activated in ovarian mucinous adenocarcinoma, and correlates with oxaliplatin resistance. Cervical adenocarcinoma is thought to have worse prognosis compared with squamous cell carcinoma due to low response to chemotherapy and radiotherapy. So new therapy has been expected for cervical adenocarcinoma. We examined src expression by immunohistochemistry in cervical adenocarcinoma treated with surgery during 2001 to 2011 and association with clinico pathological findings. 36 invasive cancers and 1 adenocarcinoma in situ (AIS) and 12 normal cervical glands were examined. In invasive cancer, src was activated in 16/36 (44%) cases, especially in 9/15 (60%) of mucinous type. Src was also activated in AIS, but not in normal cervical glands. The frequency of parametrial invasion and lymphnode metastasis in Src positive and negative cases were 1/15 (7%) versus 1/18 (6%) and 2/15 (13%) versus 3/20 (15%) in respectively. There were no statistical differences between src positive and negative cases. 3 cases in src positive and 1 case in src negative recurred. Moreover, src was activated in I case of AIS, but not activated in adjacent normal gland. In summary, src activation is an early event in the carcinogenesis of cervical adenocarcinoma, and has possibility to be a new target in the treatment of cervical adenocarcinoma. Citation Format: Masato Nishimura, Natsumi Tanimura, Takako Kawakita, Kanako yoshidaa, Minoru Irahara. Src is activated in cervical adenocarcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1591. doi:10.1158/1538-7445.AM2014-1591